Pediatric Chronic Kidney Disease Study in Georgia

A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of a study drug for Oral Suspension in Children and Adolescents (2 to < 18) with Chronic Kidney Disease has been approved at 5 sites in Georgia. AmeRuss will be cooperating with another multinational CRO as a part of a global team providing full service support for this trial. This protocol provides AmeRuss another opportunity to demonstrate our expertise in recruitment and management of a challenging patient population and to further its comprehensive acumen in pediatric clinical trials. AmeRuss anticipates that the rate of recruitment and quality of data from the Georgian sites will constitute a major contribution to the successful completion of this multinational study.